Immunoassay for detecting acino-foetal differention protein asso

Chemistry: analytical and immunological testing – Biospecific ligand binding assay

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

436506, 436518, 436530, 436548, 436526, 436806, 436808, 436813, 436804, 436544, 436545, 436546, 435 7, 435810, 530387, 530395, 424 858, G01N 3353, G01N 33533, G01N 33534

Patent

active

048430196

DESCRIPTION:

BRIEF SUMMARY
The present invention relates to acino-fetal differentiation proteins associated with cancer of the pancreas, to their purification, to a specific antiserum and the preparation thereof, to monoclonal antibodies specific for these proteins and the process for preparation thereof, and also to the compositions for diagnostic use and therapeutic use containing them.
The demonstration of the presence, in extracts of fetal pancreas, of antigens similar to those of pancreatic tumor cells is known.
Human oncofetal pancreatic antigens have been identified, having a molecular weight of 40 KD (POA-1) [banwo o., Versey J. and Hobbs J. R., New Oncofetal antigen for human pancreas. Lancet, 1: 643-645, 1974 ; Hobbs J. R., Knapp, M. L. and Branfoot A. G. Pancreatic oncofetal antigen (POA): its frequency and localisation in humans. Oncod. Biol. and Medicine, 1: 37-48, 1980], 800 and 900 KD (POA-2) [Gelder F. B., Resse C. J., Moossa A. R., Hall T. and Hunter R. Purification partial characterization and clinical evaluation of a pancreatic oncofetal antigen. Cancer Res. 38: 313-324, 1978] and 1,000 KD (PCAA) (Shimano T., Loor R. M. Papsidero L. D. et al. Isolation, characterization and clinical evaluation of a pancreas cancer associated antigen. Cancer., Supplement, 47: 1602-1620, 1981]. However, none of these antigens is specific to cancer of the pancreas, since they occur in tissues other than pancreatic cancerous tumors.
The present invention relates to acion-fetal (sic) differentiation proteins associated with cancer of the pancreas, these proteins being mannoside-containing glycoproteins, of average apparent molecular mass chosen from: 120 KD, 94 KD, 75 KD and 58 KD.
The present invention also relates to a method for preparing these proteins, wherein a soluble homogenate of human fetal pancreas is prepared and wherein a fraction consisting of mannoside-containing glycoproteins is isolated.
The method for preparing these antigens comprises the following stages: concanavalin A coupled to a gel in order to bind the said proteins,
The preparation of the homogenate is described in Example 1.
Young fetuses of gestational age less than 6 months, and preferably less than 5 months, are used because the proteins according to the invention do not appear in the adult pancreas and because rabbits injected with pancreas from fetuses older than 6 months did not produce detectable antibodies.
In a particular embodiment, a gel of Sepharose 4B coupled to concanavalin A, marketed by Pharmacia, was used. The unbound fraction is removed, and the bound fraction is eluted using a specific ligand, e.g. 0.2 M .alpha.-methylmannoside. The eluted bound fraction is then dialyzed by a conventional technique and the proteins are separated, for example by preparative electrophoresis. The peaks corresponding to the proteins according to the invention have been identified beforehand by qualitative electrophoresis.
The acrylamide gel fractions charged with proteins according to the invention are then removed and the proteins are extracted therefrom by electroelution in a dialysis tube against PBS phosphate buffer (saline solution 0.15 M NaCl buffered to pH 7 with potassium phosphate buffer, 0.01 M final concentration). The proteins are dialyzed against distilled water and lyophilized. A characterization of the proteins according to the invention is described in Example 6.
To separate the differentiation proteins, the techniques of immune binding to the monoclonal antibodies can also be used.
The present invention also relates to an antiserum against the antigens according to the invention.
By application of the blotting technique (after acrylamide gel electrophoresis--PAGE--the proteins which have migrated into the gel are transferred electrophoretically to a nitrocellulose sheet; this sheet is then treated as in the NIF technique), this antiserum recognizes, in the extracts of fetal pancreas, 4 constituents of average apparent molecular mass 120, 94, 75 and 58 KD (to within 10%).
The present invention also relates to a method for preparing this antiseru

REFERENCES:
patent: 4686180 (1987-08-01), Coggins et al.
Escribano et al., CA vol. 105, 1986, #151087w.
Llopis et al. Biochemica et Biophys Acta 880, 1986, pp. 101-107.
Nilson et al., Biochem Biophys Acta 835, 1985, pp. 577-583.
Escribano et al. 14th Int Cancer Congress 1986, (Biosis Abst).
Escribano et al. Int J Cancer 38(2) 1982, 155-60 (Biosis Abst).
Parsa et al., Int J. Pancreatul 1, 1986 61-70 (Biosis Abst).
Kondo et al. CA vol. 96, 1982, #48642v.
Homma, vol. 98, 1983, #141650x.
Chemical Abstracts, vol. 96, No. 11, 15 Mar. 1982, p. 443, Ref. No. 83845k, W. H. Schmiegel et al.: "Pancreatic Oncofetal Antigen in Pancreatic Juices . . . ".
Chemical Abstracts, vol. 90, No. 21, 21 May 1979, p. 425, Ref. No. 177378n, S. R. Harvey et al. "An Immunoglobulin M (IgM) Antibody to Carcinoembryonic Antigen (CEA)-Like . . . ".
Chemical Abstracts, vol. 87, No. 23, 5 Dec. 1977, p. 451, Ref. No. 182455d, R. Fritsche et al.: "Betaonocofoetal Antigen (BOFA) Associated with Several Types . . . ".
Chemical Abstracts, vol. 87, No. 11, 12 Sep. 1977, p. 443, Ref. No. 82921n, R. Fritsche et al.: "Betaoncofetal Antigen (BOFA) Associated with Several . . . ".
Chemical Abstracts, vol. 96, No. 7, 15 Feb. 1982, p. 220, Ref. No. 48642v, Columbus, Ohio, U.S.; JP-A-81 135 422 (Sanyo Chemical Industries Ltd.) 22.10.1981.
Chemical Abstracts, vol. 91, No. 21, 19 Nov. 1979, p. 479, Ref. No. 173027W, K. Nishia et al.,: "Assay of Pancreatic Carcinoembryonic Antigen in Pancreatic . . . ".
Chemical Abstracts, vol. 85, No. 17, 25 Oct. 1976, p. 463, Ref. No. 121577g, T. Yamanoto et al.,: "Heterogeneity of Carcinoembryonic Antigen . . . ".
Chemical Abstracts, vol. 95, No. 23, 7 Dec. 1981, p. 497, Ref. No. 201826j, T. Homma et al.: "A Pancreatic Onocofetal Antigen: Its Partial . . . ".
Chemical Abstracts, vol. 98, No. 17, 25 Apr. 1983, p. 434, Ref. No. 141650x, T. Homma: "Pancreatic Oncofetal Antigen (POA) Its Characterization . . . ".

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immunoassay for detecting acino-foetal differention protein asso does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoassay for detecting acino-foetal differention protein asso, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoassay for detecting acino-foetal differention protein asso will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-813402

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.